

Omentin-1 induces osteoblast viability and differentiation via the TGF- β /Smad signaling pathway in osteoporosis

CUISONG TANG^{1*}, DENG PAN LIANG^{2*}, YUYOU QIU³, JINGQI ZHU³ and GUANGYU TANG¹

¹Department of Radiology, Clinical Medical College of Shanghai Tenth People's Hospital of Nanjing Medical University, Shanghai 200072; ²Department of Cardiology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500; ³Department of Radiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China

Received November 24, 2020; Accepted July 13, 2021

DOI: 10.3892/mmr.2022.12648

Abstract. Osteoporosis is a bone-related disease that results from impaired bone formation and excessive bone resorption. The potential value of adipokines has been investigated previously, due to their influence on osteogenesis. However, the osteogenic effects induced by omentin-1 remain unclear. The aim of the present study was to determine the regulatory effects of omentin-1 on osteoblast viability and differentiation, as well as to explore the underlying molecular mechanism. The present study investigated the effects of omentin-1 on the viability and differentiation of mouse pre-osteoblast cells (MC3T3-E1) using quantitative and qualitative measures. A Cell Counting Kit-8 assay was used to assess the viability of MC3T3-E1 cells following treatment with different doses of omentin-1. Omentin-1 and bone morphogenetic protein (BMP) inhibitor were added to osteogenic induction mediums in different ways to assess their effect. The alkaline phosphatase (ALP) activity and Alizarin Red S (ARS) staining of MC3T3-E1 cells treated with omentin-1 and/or BMP inhibitor were used to examine the effects of omentin-1 on differentiation and mineralization. Western blotting was used to further explore its potential mechanism, and to study the role of omentin-1 on the viability and differentiation of osteoblasts. The results showed that omentin-1 altered the viability of MC3T3-E1 cells in a dose-dependent manner. Omentin-1 treatment significantly increased the expression of members of the TGF- β /Smad signaling pathway. In the omentin-1 group, the ALP activity of the MC3T3-E1 cells was increased, and the ARS staining area was also increased. The mRNA

and protein expression levels of BMP2, Runt-related transcription factor 2, collagen1, osteopontin, osteocalcin and osterix in the omentin-1 group were also significantly upregulated. All these effects were reversed following treatment with SIS3 HCl. These results demonstrated that omentin-1 can significantly promote osteoblast viability and differentiation via the TGF- β /Smad signaling pathway, thereby promoting bone formation and preventing osteoporosis.

Introduction

Osteoporosis is a debilitating disease that predominantly affects elderly individuals worldwide (1). At present, >200 million patients suffer from osteoporosis worldwide (2). According to research statistics, >1.6 million fractures are caused by osteoporosis (3,4). For women aged >50 years, the risk of suffering from fractures due to osteoporosis is 40-50% (5). Osteoporosis is a systemic skeletal disease that is characterized by a decrease in mass and deterioration of the bone microstructure (6). The consequences brought on by osteoporosis are bone fragility and susceptibility to fractures, and this can cause brittle fractures (7). At the cellular level, the pathogenesis of osteoporosis is primarily related to the disruption of bone remodeling (8). Bone remodeling primarily depends on osteoblast osteogenesis and osteoclast bone absorption, so as to maintain a certain balance (9). When a disease or aberrant inflammation disrupt this balance, osteoporosis may occur (10).

In bone tissues, osteoblasts originate from mesenchymal stem cells (MSCs), whereas osteoclasts are derived from hematopoietic stem cells (11). The differentiation of osteoblasts is achieved through the initial organic phase, which is production of collagen matrix, and the final inorganic phase, which is mineralization by hydroxyapatite crystals on the collagen scaffold (12). After the completion of matrix secretion and mineralization, the osteoblasts, which are embedded in the matrix, are known as bone cells, whereas the osteoblasts remaining on the bone surface turn into flattened lining cells or gradually undergo apoptosis. Importantly, bone marrow MSCs (BMSCs) are pluripotent. Apart from osteoblasts, BMSCs can differentiate into several different cell types, including adipocytes, myocytes, chondrocytes, endothelial

Correspondence to: Dr Guangyu Tang, Department of Radiology, Clinical Medical College of Shanghai Tenth People's Hospital of Nanjing Medical University, 301 Middle Yanchang Road, Shanghai 200072, P.R. China
E-mail: tgy17tjy@163.com

*Contributed equally

Key words: omentin-1, osteoblasts, osteoporosis, TGF- β /Smad signaling pathway

cells and vascular smooth muscle cells (13). Amongst these cell lineages, adipogenic differentiation is particularly relevant to the homeostasis of bone, as cells undergoing osteoblast formation can be diverted to adipocytes, leading to the loss of these cells from the osteoblast pool and the reduction of overall osteogenic potential (13).

The imbalance of adipocyte differentiation and regulation of osteoblasts is commonly seen in aging and diabetic individuals, which can lead to the impairment of fat bone marrow, impairment of osteoblast renewal and an increase in the incidence of chronic bone loss (13-15). Beyond that, adipocytes secrete a series of biologically active signaling molecules, which can also influence bone homeostasis. It has been reported that several of these molecules, including chemorin, resistin, visfatin, leptin and adiponectin, affect the development and function of osteoblasts and osteoclasts (16-21).

Omentin-1, a 34 kDa adipokine selectively expressed in omental adipose tissue, is abundant in the plasma (22,23). Omentin-1 has been demonstrated to serve as a significant factor in multiple physiological processes, including insulin action, cardiovascular function and the inflammatory response (23-25). A previous study demonstrated that omentin-1 plays an important role in protecting against vascular calcification (26). A clinical study has also shown that omentin-1 levels are inversely correlated with obesity and insulin resistance (27). Regarding its effects on bone, a previous study reported that circulating omentin-1 levels were inversely correlated with bone mineral density (BMD) in the lumbar region of the spine in Iranian postmenopausal women (28). The levels of circulating omentin-1 correlates positively with adiponectin and negatively with body mass index and the leptin levels (29). In a co-culture system of osteoblasts and osteoclast precursors, omentin-1 can reduce osteoclast formation by stimulating osteoprotegerin (OPG) (30). To date, only a few studies have investigated the association between omentin-1 and osteoblast proliferation and differentiation. Moreover, the osteogenic effect induced by omentin-1 remains unclear. The TGF- β /Smad signaling pathway is involved in the regulation of cell differentiation and it is a key pathway related to osteogenesis (31-33). To understand the underlying mechanism driving the effects of omentin-1 on osteogenic differentiation in MC3T3-E1, the role of the TGF- β /Smad pathway in this process was investigated. The aim of the present study was to determine the regulatory effects of omentin-1 on osteoblast viability and differentiation, as well as to explore the underlying molecular mechanism.

Materials and methods

Cell culture and treatment. Mouse embryo osteoblast precursor cell line MC3T3-E1 was obtained from American Type Culture Collection (ATCC, CRL-2593TM). The cells were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (HyClone; Cytiva) and 1% penicillin/streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C in a 5% CO₂ humidified incubator. In order to stimulate osteogenic induction, the MC3T3-E1 cells were seeded in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, 10 mM β -glycerophosphate, 50 μ g/ml ascorbic acid and 10 nM dexamethasone (all Sigma-Aldrich;

Merck KGaA) (34). Subsequently, cells were treated with different doses of omentin-1 (100, 500 and 1,000 ng/ml; Cell Science, Inc.) for 24 h at 37°C and/or 3 μ M SIS3 HCl (Selleck Chemicals) for 6 h at 37°C for the following experiments.

Reverse transcription-quantitative (RT-q)PCR. Total RNA was extracted from cells using TRIzol[®] reagent (Invitrogen; Thermo Fisher Scientific, Inc.). iScript[™] Reverse Transcription SuperMix kit (Bio-Rad Laboratories, Inc.) was used to reverse transcribe 2 μ g RNA into cDNA according to the manufacturer's protocol. qPCR was performed using SYBR-Green MasterMix (Applied Biosystems; Thermo Fisher Scientific, Inc.) on an ABI PRISM 7900 Sequence Detection system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The PCR amplification program was as follows: 94°C for 60 sec, followed by 40 cycles of 94°C for 30 sec, 60°C for 30 sec and 72°C for 60 sec. The primer sequences used for PCR were as follows: Bone morphogenetic protein 2 (BMP2) forward, 5'-AGCCCTTCACTGCCATCCTGT-3' and reverse, 5'-ATTCTCTCGTTCACCGCCAC-3'; Runt-related transcription factor 2 (Runx2) forward, 5'-CCCAACTTCCTGTGCTCC-3' and reverse, 5'-AGTGAACTCTTGCCCTCGTC-3'; Collagen1 forward, 5'-TAAGGGTGACAGAGGCGATG-3' and reverse, 5'-GGA CCGCTAGGACCAGTTTC-3'; osteopontin (Opn) forward, 5'-TCCAAAGTCAGCCAGGAATCC-3' and reverse, 5'-CGG AGTTGTCTGTGCTCTTCA-3'; osteocalcin (Ocn) forward, 5'-CTCCTTACCCGGATCCCCTG-3' and reverse, 5'-GTA GAAGCGCTGGTAGGCGT-3'; Osterix forward, 5'-TCCCTG GATATGACTCATCCCT-3' and reverse, 5'-CCAAGGAGT AGGTGTGTTGCC-3'; and GAPDH forward, 5'-GGGAAA CTGTGGCGTGAT-3' and reverse, 5'-GAGTGGGTGTCTGCTTGA-3'. Gene expression analysis was performed using the 2^{- $\Delta\Delta C_q$} method (35) and normalized to GAPDH.

Cell viability. The cells were cultured in 96-well culture plates at a density of 2x10⁴ cells/well. After 3 days, a Cell Counting Kit-8 (CCK-8) assay (Beyotime Institute of Biotechnology) was performed to evaluate cell viability. The CCK-8 solution was added to each group, and the cells were incubated at 37°C for 1 h. The absorbance of each well was measured at a wavelength of 450 nm using a microplate spectrophotometer.

Western blot assay. Cells in the different treatment groups were lysed using RIPA lysis buffer (Beyotime Institute of Biotechnology) and protein concentrations were measured using Bradford reagent (Bio-Rad Laboratories, Inc.). Equal quantities of proteins (40 μ g/lane) were separated via 10% SDS-PAGE (Bio-Rad Laboratories, Inc.) and transferred to a PVDF membrane (MilliporeSigma). After being blocked with 5% non-fat milk in 0.1% tris-buffered saline with Tween-20 for 1 h at room temperature, the membranes were incubated with primary antibodies against BMP2 (1:1,000; cat. no. ab214821; Abcam), phosphorylated (p)-Smad1 (1:1,000; cat. no. ab226821; Abcam), p-Smad5 (1:2,000; cat. no. ab92698; Abcam), Smad1 (1:1,000; cat. no. ab33902; Abcam), Smad5 (1:1,000; cat. no. ab40771; Abcam), Runx2 (1:1,000; cat. no. ab236639; Abcam), collagen1 (1:1,000; cat. no. ab138492; Abcam), Opn (1:1,000; cat. no. ab63856; Abcam), Ocn (1:1,000; cat. no. ab133612; Abcam) and osterix (1:1,000; cat. no. ab209484; Abcam) and GAPDH (1:2,500;

cat. no. ab9485; Abcam) overnight at 4°C, and then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (1:1,000; cat. no. #7074; Cell Signaling Technology, Inc.) for 1 h at room temperature. The blots were then visualized using an enhanced chemiluminescence system (Beyotime Institute of Biotechnology). Densitometry analysis was performed using ImageJ (Version 1.49; National Institutes of Health).

Cell differentiation analysis. Alkaline phosphatase (ALP) activity, an early biochemical marker widely used to assess osteogenic activity, was measured. Briefly, the cells were seeded in 12-well culture plates at a density of 4×10^4 cells per ml for 7 days. Subsequently, the cells were fixed in 4% paraformaldehyde for 30 min at room temperature, followed by treatment with nitroblue tetrazolium (Sigma-Aldrich; Merck KGaA) and 5-bromo-4-chloro-3-indolyl phosphate (Sigma-Aldrich; Merck KGaA) for 2 h at room temperature. Cells were washed with deionized water and observed under an inverted light microscope (Nikon Corporation; x200 magnification).

Cell mineralization analysis. Mineralization was evaluated by quantifying the formation of calcium phosphate in cells using an Alizarin Red Staining (ARS) kit (Sigma-Aldrich; Merck KGaA). Briefly, the cells were cultured in 12-well culture plates at a density of 4×10^4 cells per ml. After 21 days, the cultured cells were fixed with 95% ethanol for 10 min at room temperature. To stain the calcium deposits, 2% ARS solution (Sigma-Aldrich; Merck KGaA) was applied for 15 min at room temperature. To measure the degree of mineralization, the ARS released from the cell matrix was incubated in cetyl pyridinium chloride for 15 min at room temperature and quantified by spectrophotometry at 540 nm.

Statistical analysis. Data are presented as the mean \pm standard deviation of three independent experiments. Differences between groups were determined using an unpaired two-tailed Student's t-test for comparisons between two groups, and one-way ANOVA with a post hoc Tukey's test was used for comparisons between multiple groups. Statistical analysis was performed using SPSS 13.0 (SPSS, Inc.). $P < 0.05$ was considered to indicate a statistically significant difference.

Results

Omentin-1 stimulates viability of osteoblasts. The effect of omentin-1 on MC3T3-E1 cell viability was assessed using a CCK-8 assay. As shown in Fig. 1, the viability of osteoblasts was altered in a dose-dependent manner following treatment with omentin-1, and the effect was significant when treated with 1,000 ng/ml omentin-1 after 3 days of treatment.

Omentin-1 activates the Smad signaling pathway and increases BMP2 expression in osteoblasts. To explore the potential mechanisms by which omentin-1 exerted its effects on osteoblasts, western blotting was performed. As shown in Fig. 2, omentin-1 at a dose of 1,000 ng/ml increased the protein expression levels of BMP2, p-Smad1 and p-Smad5 ($P < 0.05$). However, 1,000 ng/ml omentin-1 did not exert a notable effect on the expression levels of Smad1 and Smad5.




Figure 1. Effects of different concentrations of omentin-1 on the viability of MC3T3-E1 cells. Cell Counting Kit-8 assay was performed to assess cell viability. Results are expressed as the mean \pm SD. *** $P < 0.001$ vs. control.

Omentin-1 promotes the viability of osteoblasts through the TGF- β /Smad signaling pathway. As shown in Fig. 3A and B, SIS3 HCl, a Smad inhibitor, significantly inhibited BMP2 protein levels and phosphorylation of Smad1 and Smad5 compared with the control group, while 1,000 ng/ml omentin-1 significantly increased the expression levels of the three proteins. Meanwhile, SIS3 HCl attenuated the effects of omentin-1 on the expression of BMP2, p-Smad1 and p-Smad5 in MC3T3-E1 cells. In addition, CCK-8 analysis showed a significant increase in cell viability in omentin-1-treated MC3T3-E1 cells, and this increase in viability was significantly attenuated by SIS3 HCl (Fig. 3C).

Omentin-1 regulates differentiation and mineralization of osteoblasts via the TGF β /Smad signaling pathway. Next, the effects of omentin-1 on osteoblasts were assessed. As shown in Fig. 4A and B, ARS staining in the omentin-1-treated cells showed an increased mineralization rate compared with the control group, and SIS3 HCl significantly attenuated the omentin-1-induced mineralization. In addition, ALP activity was significantly increased in the omentin-1 group, whereas SIS3 HCl significantly weakened the activity of ALP in MC3T3-E1 cells (Fig. 4C).

Analysis of cellular Runx2, collagen1, Opn, Ocn and osterix expression. Data from RT-qPCR and western blot assays showed that the expression levels of osteogenesis-related proteins, including BMP2, Runx2, collagen1, Opn, Ocn and osterix, were significantly upregulated in the omentin-1 group. However, the expression levels of these proteins in MC3T3-E1 cells treated with SIS3 HCl were significantly reduced (Fig. 5A-C).

Discussion

Bone remodeling and skeletal homeostasis are dynamic life-long processes that rely on the balance and integrated actions between osteoblastic bone formation and osteoclastic bone resorption (36-38). Osteoblastic lineage cells interact with osteoclastic lineage cells, which is necessary for the formation of functional osteoclasts (39). Certain bone-related diseases, such as osteoporosis, rheumatoid arthritis and




Figure 2. Effects of omentin-1 on the expression of genes related to the TGF-β/Smad pathway. Western blotting was used to detect the protein levels of the TGF-β/Smad pathway. Results are expressed as the mean ± SD. **P<0.01, ***P<0.001 vs. control. TGF-β, transforming growth factor-β; BMP2, bone morphogenetic protein 2; p-, phosphorylated.




Figure 3. Effects of omentin-1/TGF-β/Smad signaling on the viability of osteoblasts and quantitative analyses. (A and B) Western blot assay was utilized to measure the protein levels of TGF-β/Smad pathway. (C) Cell viability was evaluated via a Cell Counting Kit-8 assay. Results are expressed as the mean ± SD. *P<0.05, **P<0.01, ***P<0.001 vs. control; #P<0.05, ##P<0.01, ###P<0.001 vs. SIS3 HCl group; ΔP<0.05, ΔΔP<0.001 vs. 1,000 ng/ml omentin-1 group. TGF-β, transforming growth factor-β; BMP2, bone morphogenetic protein 2; p-, phosphorylated.

osteoarthritis, are associated with abnormal bone metabolism and accelerated bone loss (40). Bone formation and repair are intrinsically associated with the balanced activity of osteoblasts (41). Osteoblasts are responsible for bone matrix secretion and mineralization, and they tightly regulate osteoclast activation and differentiation (42). Dysfunctional behaviors of osteoblasts lead to improper bone matrix deposition and mineralization, affecting the size, shape and integrity of the skeletal structures (43).

MC3T3-E1, a popular osteoblast cell line that represents a pre-osteoblastic phenotype, is a mouse calvaria clonal cell line that has given rise to several subclones (44). Decreased proliferative activities have been observed at passage numbers above 36, whereas their replicative senescence has been displayed when these cells reach a high passage number of 60, which is similar to that of human cells, at which point they show inconsistent cell cycling (45). This important feature also makes these cells suitable as novel models




Figure 4. Effects of omentin-1/transforming growth factor- β /Smad signaling on the differentiation and mineralization of osteoblasts. (A and B) Mineralization was identified by an Alizarin Red Staining kit. Original magnification, x200. (C) ALP activity was measured using an ALP kit. *** $P < 0.001$ vs. control; # $P < 0.05$ vs. SIS3 HCl group; $\Delta\Delta\Delta P < 0.001$ vs. 1,000 ng/ml omentin-1 group. ALP, alkaline phosphatase.

for *in vitro* bone research, including bone remodeling and formation (46).

Omentin-1, which was discovered from a human omental fat cDNA library, is primarily expressed in visceral adipose tissue (23). Omentin-1 can promote osteogenic differentiation, although this has been contested (47-52). Therefore, the present study investigated the effects of omentin-1 on MC3T3-E1 cells by observing proliferation patterns, with the aim of determining the regulatory effect of omentin-1 and identifying the underlying molecular mechanisms. When MC3T3-E1 cells were treated with different concentrations of omentin-1 (100-1,000 ng/ml) for 3 days, the viability of MC3T3-E1 cells increased significantly. Additionally, the effect of omentin-1 was weakened after adding a BMP inhibitor. This suggested that omentin-1 could stimulate the viability of osteoblasts. Based on these experiments, 1,000 ng/ml omentin-1 was used for subsequent experiments, and 0 ng/ml omentin-1 was used as the control group to further study the effects of omentin-1 on osteoblasts.

Regulation of gene expression by TGF- β is achieved primarily through the initiation of intracellular signal transduction and the activation of the Smad signaling pathway (53,54). TGF- β promotes osteogenic differentiation, and at the same time, it also inhibits adipogenic differentiation of human MSCs (55). The TGF- β /Smad pathway is also key to adipogenesis (56). TGF- β inhibits adipogenic differentiation in human preadipocytes, which is mediated primarily by the Smad family members (57,58). Smad3 inhibits adipogenic conversion, whereas interfering with Smad3 function confers resistance to inhibition of adipogenesis by TGF- β (56). The

present results showed that SIS3 HCL treatment significantly inhibited the protein expression levels of BMP2, p-SMAD1 and p-SMAD5, while 1,000 ng/ml omentin-1 increased the protein expression levels of BMP2 and p-Smad1/5. However, 1,000 ng/ml omentin-1 exerted no effect on Smad1 and Smad5, which are also members of the TGF- β /Smad pathway.

To confirm the effects of the omentin-1/TGF- β /Smad pathway on MC3T3-E1 cells, cells were pretreated with a selective BMP TGF- β /Smad signaling inhibitor, SIS3 HCl (3 μ M per day), 3 days prior to treatment with 1,000 ng/ml omentin-1. Cell viability was promoted in the 1,000 ng/ml omentin-1 group, and SIS3 HCl attenuated the increase in viability mediated by omentin-1. The results from the CCK-8 assays revealed that omentin-1 significantly promoted the viability ability of the MC3T3-E1 cells via the TGF- β /Smad pathway.

In previous years, several studies have investigated the relationship between omentin-1 and bone metabolism. On the one hand, adiponectin has been shown to induce osteoblast proliferation and differentiation (50), as well as to increase bone mass via osteoclastogenesis suppression and osteoblastogenesis activation (51), and the results of the present study were in agreement with these previous findings. Conversely, adiponectin has been verified to induce osteoclast formation via stimulation of RANKL and inhibition of OPG production (48,49). This suggests that adipokines also serve an important role in osteoclastic balance; thus the effects of adipokines on osteoclasts should form the basis of future studies. A previous study showed that there was an inverse correlation between omentin-1 and broadband ultrasound




Figure 5. Effects of omentin-1/transforming growth factor- β /Smad signaling on the expression of genes related to bone formation. (A and B) Western blotting analysis was applied for protein detection of BMP2, Runx2, Collagen1, Opn, Ocn and Osterix. (C) mRNA levels of BMP2, Runx2, Collagen1, Opn, Ocn and Osterix were measured by reverse transcription-quantitative PCR. *** $P < 0.001$ vs. control; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ vs. SIS3 HCl group; $\Delta P < 0.05$, $\Delta\Delta P < 0.01$, $\Delta\Delta\Delta P < 0.001$ vs. 1,000 ng/ml omentin-1 group. BMP2, bone morphogenetic protein 2; Runx2, runt-related transcription factor 2; Opn, osteopontin; Ocn, osteocalcin.

attenuation levels in postmenopausal women. This association was not mediated by OPG levels (52). The results from *in vitro* and *in vivo* studies have shown contradictory results. Results from a meta-analysis of observational studies demonstrated an inverse relationship between adiponectin levels and BMD, with five studies showing a negative association, and another five showing no association (47). The reasons for such discrepant findings are unclear, but it is conceivable that the microenvironment in human bodies can be affected by various factors. The ability of cell culture and animal models to emulate the complex processes that take place in the human body is limited, such as possible adiponectin-dependent counter-regulatory mechanisms.

Osteoporosis, a type of bone-related disease, results from impaired bone formation and excessive bone resorption. Current strategies to augment bone formation, such as the use of growth factors (59), have shown promising results. However, the osteoblast lineage specification and bone regeneration remain unclear. An improved understanding of these may considerably improve the therapeutic strategies available.




Figure 6. Proposed schematic diagram for the regulatory effects of omentin-1 on the viability and differentiation of osteoblasts via the transforming growth factor- β /Smad signaling pathway in osteoporosis. BMP2, bone morphogenetic protein 2.

In order to determine how omentin-1 guides osteoblast bone formation, the effects of several potential mediators involved in the pro-osteogenic pathway were assessed using western blotting in the current study. Osteoblasts are derived from osteoprogenitors that differentiate by progressively expressing maturation markers (60). Runx2 is a transcription factor that serves a role in osteoblast differentiation. Previous studies have shown that silencing of Runx2 can block the differentiation of osteoblasts in mice (61,62). Patients with cleidocranial dysplasia, which is caused by heterozygous mutations in the Runx2 gene, are characterized by an underdeveloped collarbone, short stature, excess teeth, fontanelle patency and other bone growth-related defects (63). Osterix is a zinc finger transcription factor present in osteoblasts and serves a leading role in the osteoblast differentiation process (63). A previous study showed that Runx2 can regulate the levels of osterix (64). Collagen-1 is a primary structural protein present in the extracellular space in the bone, making up 25-35% of the entire-body protein content (65). Depending upon the degree of mineralization, collagen tissues may be rigid (bone), compliant (tendon) or have a gradient from rigid to compliant (cartilage) (66). As the skeleton is the main structural component of the body, collagen-1 is responsible for maintaining the strength of these structures (67). Opn is also known as bone sialoprotein I, a protein in humans encoded by the SPP1 gene (68). Ocn is a vitamin K-dependent calcium-binding protein (69). Opn and Ocn are two typical biomarkers of osteoblasts, and are involved in osteogenic differentiation and the mineralization of extracellular matrix during bone formation and repair (70,71). Previous studies have shown that Runx2 stimulates the differentiation of MSCs into osteoblasts by regulating Opn and Ocn activity (61,72). In the present study, it was shown that omentin-1 significantly upregulated the expression of Runx2, Collagen-1, Opn, Ocn and osterix, suggesting that it accelerated bone formation.

Based on the aforementioned results, it was noticed in the present study that SIS3 HCL treatment alone only affected the TGF- β /Smad pathway, but had no significant effects on the viability, differentiation and mineralization of osteoblasts and the expression of osteogenesis-related proteins. However, SIS3 HCL exerted obvious roles when the cells were treated with omentin-1. Hence, we speculated that under normal conditions, osteoblasts were only partially affected by SIS3 HCL except for the expression of TGF- β /Smad pathway, but omentin-1 had significant promoting effects on cell differentiation and mineralization via regulating the TGF- β /Smad pathway. Thus, there is a noticeable effect of SIS3 HCL on biological function and signaling and omentin-1-mediated osteoblasts.

In conclusion, the present study examined the potential effects of omentin-1 on the viability and differentiation of osteoblasts and the signaling pathways involved (Fig. 6). Omentin-1 promoted osteoblast viability in a dose-dependent manner. Western blotting revealed that omentin-1 induced the activation of BMP2 and p-Smad1/5. Furthermore, omentin-1 promoted osteoblast viability, differentiation and mineralization, and these effects were impeded by a TGF- β /Smad inhibitor. These findings indicated that omentin-1 promoted osteoblast viability and differentiation via the TGF- β /Smad signaling pathway, suggesting that omentin-1 may be a potential target in the treatment of osteoporosis.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

CT, DL and GT designed the study, drafted and revised the manuscript. YQ and JZ analyzed the data and searched the literature. CT, DL, YQ and JZ performed the experiments. CT and GT confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Miller PD: Management of severe osteoporosis. *Expert Opin Pharmacother* 17: 473-488, 2016.
2. Noh JY, Yang Y and Jung H: Molecular mechanisms and emerging therapeutics for osteoporosis. *Int J Mol Sci* 21: 7623, 2020.
3. Clark S: Osteoporosis-the disease of the 21st century? *Lancet* 359: 1714, 2002.
4. Cooper C: Epidemiology of osteoporosis. *Osteoporos Int* 9 (Suppl 2): S2-S8, 1999.
5. Johnell O and Kanis J: Epidemiology of osteoporotic fractures. *Osteoporos Int* 16 (Suppl 2): S3-S7, 2005.
6. Straka M, Straka-Trapezanlidis M, Deglovic J and Varga I: Periodontitis and osteoporosis. *Neuro Endocrinol Lett* 36: 401-406, 2015.
7. Kurra S, Fink DA and Siris ES: Osteoporosis-associated fracture and diabetes. *Endocrinol Metab Clin North Am* 43: 233-243, 2014.
8. Lane NE: Epidemiology, etiology, and diagnosis of osteoporosis. *Am J Obstet Gynecol* 194 (Suppl 2): S3-S11, 2006.
9. Baccaro LF, Conde DM, Costa-Paiva L and Pinto-Neto AM: The epidemiology and management of postmenopausal osteoporosis: A viewpoint from Brazil. *Clin Interv Aging* 10: 583-591, 2015.
10. Lane JM, Russell L and Khan SN: Osteoporosis. *Clin Orthop Relat Res* 372: 139-150, 2000.
11. Chen X, Wang Z, Duan N, Zhu G, Schwarz EM and Xie C: Osteoblast-osteoclast interactions. *Connect Tissue Res* 59: 99-107, 2018.
12. Jayakumar P and Di Silvio L: Osteoblasts in bone tissue engineering. *Proc Inst Mech Eng H* 224: 1415-1440, 2010.
13. Malhotra A and Habibovic P: Calcium phosphates and angiogenesis: Implications and advances for bone regeneration. *Trends Biotechnol* 34: 983-992, 2016.

14. Leijten J, Chai YC, Papantoniou I, Geris L, Schrooten J and Luyten FP: Cell based advanced therapeutic medicinal products for bone repair: Keep it simple? *Adv Drug Deliv Rev* 84: 30-44, 2015.
15. Wei DX, Dao JW and Chen GQ: A Micro-Ark for Cells: Highly open porous polyhydroxyalkanoate microspheres as injectable scaffolds for tissue regeneration. *Adv Mater* 30: e1802273, 2018.
16. Shen X, Zhang Y, Gu Y, Xu Y, Liu Y, Li B and Chen L: Sequential and sustained release of SDF-1 and BMP-2 from silk fibroin-nanohydroxyapatite scaffold for the enhancement of bone regeneration. *Biomaterials* 106: 205-216, 2016.
17. Cahill KS, Chi JH, Day A and Claus EB: Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. *JAMA* 302: 58-66, 2009.
18. Skovrlj B, Koehler SM, Anderson PA, Qureshi SA, Hecht AC, Iatridis JC and Cho SK: Association between BMP-2 and carcinogenicity. *Spine (Phila Pa 1976)* 40: 1862-1871, 2015.
19. Xu C, Su P, Chen X, Meng Y, Yu W, Xiang AP and Wang Y: Biocompatibility and osteogenesis of biomimetic Bioglass-Collagen-Phosphatidylserine composite scaffolds for bone tissue engineering. *Biomaterials* 32: 1051-1058, 2011.
20. Zhang Y, Fan W, Ma Z, Wu C, Fang W, Liu G and Xiao Y: The effects of pore architecture in silk fibroin scaffolds on the growth and differentiation of mesenchymal stem cells expressing BMP7. *Acta Biomater* 6: 3021-3028, 2010.
21. Holzwarth JM and Ma PX: Biomimetic nanofibrous scaffolds for bone tissue engineering. *Biomaterials* 32: 9622-9629, 2011.
22. Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J and Buchler C: Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. *Biochim Biophys Acta* 1732: 96-102, 2005.
23. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC and Gong DW: Identification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin action. *Am J Physiol Endocrinol Metab* 290: E1253-E1261, 2006.
24. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M and Hara Y: Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. *Biochem Biophys Res Commun* 408: 339-343, 2011.
25. Yamawaki H, Tsubaki N, Mukohda M, Okada M and Hara Y: Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. *Biochem Biophys Res Commun* 393: 668-672, 2010.
26. Duan XY, Xie PL, Ma YL and Tang SY: Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. *Amino Acids* 41: 1223-1231, 2011.
27. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubizu K, Patil S, Schwartz A, Kligman M, *et al*: Omentin plasma levels and gene expression are decreased in obesity. *Diabetes* 56: 1655-1661, 2007.
28. Tohidi M, Akbarzadeh S, Larijani B, Kalantarhormozi M, Ostovar A, Assadi M, Vahdat K, Farrokhnia M, Sanjdideh Z, Amirinejad R and Nabipour I: Omentin-1, visfatin and adiponectin levels in relation to bone mineral density in Iranian postmenopausal women. *Bone* 51: 876-881, 2012.
29. Moreno-Navarrete JM, Catalán V, Ortega F, Gómez-Ambrosi J, Ricart W, Frühbeck G and Fernández-Real JM: Circulating omentin concentration increases after weight loss. *Nutr Metab (Lond)* 7: 27, 2010.
30. Xie H, Xie PL, Wu XP, Chen SM, Zhou HD, Yuan LQ, Sheng ZF, Tang SY, Luo XH and Liao EY: Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. *Cardiovasc Res* 92: 296-306, 2011.
31. Wang J, Wang M, Chen F, Wei Y, Chen X, Zhou Y, Yang X, Zhu X, Tu C and Zhang X: Nano-hydroxyapatite coating promotes porous calcium phosphate ceramic-induced osteogenesis via BMP/Smad signaling pathway. *Int J Nanomedicine* 14: 7987-8000, 2019.
32. Liu Z, Yu Z, Chang H, Wang Y, Xiang H, Zhang X and Yu B: Strontium-containing α -calcium sulfate hemihydrate promotes bone repair via the TGF- β /Smad signaling pathway. *Mol Med Rep* 20: 3555-3564, 2019.
33. Wang QL, Li HF, Wang DP, Liu ZY, Xiao WW, Xu LL and Yu S: Effect of GGCX on the differentiation function of osteoporosis bone marrow mesenchymal stem cells through regulating TGF β /smad signaling pathway. *Eur Rev Med Pharmacol Sci* 23: 7224-7231, 2019.
34. Kim SW, Her SJ, Park SJ, Kim D, Park KS, Lee HK, Han BH, Kim MS, Shin CS and Kim SY: Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. *Bone* 37: 359-369, 2005.
35. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc* 3: 1101-1108, 2008.
36. Lerner UH, Kindstedt E and Lundberg P: The critical interplay between bone resorbing and bone forming cells. *J Clin Periodontol* 46 (Suppl 21): 33-51, 2019.
37. Fili S, Karalaki M and Schaller B: Mechanism of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. *Cancer Lett* 283: 10-19, 2009.
38. Kearns AE, Khosla S and Kostenuik PJ: Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. *Endocr Rev* 29: 155-192, 2008.
39. Horowitz MC, Xi Y, Wilson K and Kacena MA: Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. *Cytokine Growth Factor Rev* 12: 9-18, 2001.
40. Wada T, Nakashima T, Hiroshi N and Penninger JM: RANKL-RANK signaling in osteoclastogenesis and bone disease. *Trends Mol Med* 12: 17-25, 2006.
41. Long F: Building strong bones: Molecular regulation of the osteoblast lineage. *Nat Rev Mol Cell Biol* 13: 27-38, 2011.
42. Nakamichi Y, Udagawa N, Kobayashi Y, Nakamura M, Yamamoto Y, Yamashita T, Mizoguchi T, Sato M, Mogi M, Penninger JM and Takahashi N: Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. *J Immunol* 178: 192-200, 2007.
43. Valenti MT, Dalle Carbonare L and Mottes M: Osteogenic differentiation in healthy and pathological conditions. *Int J Mol Sci* 18: 41, 2016.
44. Wan Hasan WN, Abd Ghafar N, Chin KY and Ima-Nirwana S: Annatto-derived tocotrienol stimulates osteogenic activity in preosteoblastic MC3T3-E1 cells: A temporal sequential study. *Drug Des Devel Ther* 12: 1715-1726, 2018.
45. Czekanska EM, Stoddart MJ, Richards RG and Hayes JS: In search of an osteoblast cell model for in vitro research. *Eur Cell Mater* 24: 1-17, 2012.
46. Aubin JE: Regulation of osteoblast formation and function. *Rev Endocr Metab Disord* 2: 81-94, 2001.
47. Biver E, Salliot C, Combescure C, Gossec L, Hardouin P, Legroux-Gerot I and Cortet B: Influence of Adipokines and Ghrelin on Bone Mineral Density and Fracture Risk: A systematic review and meta-analysis. *J Clin Endocrinol Metab* 96: 2703-2713, 2011.
48. Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD and Liao EY: Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. *J Bone Miner Res* 21: 1648-1656, 2006.
49. Wang QP, Li XP, Wang M, Zhao LL, Li H, Xie H and Lu ZY: Adiponectin exerts its negative effect on bone metabolism via OPG/RANKL pathway: An in vivo study. *Endocrine* 47: 845-853, 2014.
50. Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP and Liao EY: Adiponectin stimulates human osteoblast proliferation and differentiation via the MAPK signaling pathway. *Exp Cell Res* 309: 99-109, 2005.
51. Oshima K, Napei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, Yoshikawa H and Shimomura I: Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. *Biochem Biophys Res Commun* 331: 520-526, 2005.
52. Wu SS, Liang QH, Liu Y, Cui RR, Yuan LQ and Liao EY: Omentin-1 stimulates human osteoblast proliferation through PI3K/Akt signal pathway. *Int J Endocrinol* 2013: 368970, 2013.
53. Miyazono K: TGF-beta signaling by Smad proteins. *Cytokine Growth Factor Rev* 11: 15-22, 2000.
54. ten Dijke P, Miyazono K and Heldin CH: Signaling inputs converge on nuclear effectors in TGF-beta signaling. *Trends Biochem Sci* 25: 64-70, 2000.
55. van Zoelen EJ, Duarte I, Hendriks JM and van der Woning SP: TGF β -induced switch from adipogenic to osteogenic differentiation of human mesenchymal stem cells: Identification of drug targets for prevention of fat cell differentiation. *Stem Cell Res Ther* 7: 123, 2016.
56. Santibanez JF and Kocic J: Transforming growth factor- β superfamily, implications in development and differentiation of stem cells. *Biomol Concepts* 3: 429-445, 2012.

57. Petruschke T, Röhrig K and Hauner H: Transforming growth factor beta (TGF-beta) inhibits the differentiation of human adipocyte precursor cells in primary culture. *Int J Obes Relat Metab Disord* 18: 532-536, 1994.
58. Choy L, Skillington J and Derynck R: Roles of autocrine TGF-beta receptor and Smad signaling in adipocyte differentiation. *J Cell Biol* 149: 667-682, 2000.
59. El Bialy I, Jiskoot W and Reza Nejadnik M: Formulation, delivery and stability of bone morphogenetic proteins for effective bone regeneration. *Pharm Res* 34: 1152-1170, 2017.
60. Rutkovskiy A, Stensløkken KO and Vaage IJ: Osteoblast differentiation at a glance. *Med Sci Monit Basic Res* 22: 95-106, 2016.
61. Yang D, Okamura H and Qiu L: Upregulated osterix expression elicited by Runx2 and Dlx5 is required for the accelerated osteoblast differentiation in PP2A α -knockdown cells. *Cell Biol Int* 42: 403-410, 2018.
62. Komori T: Runx2, an inducer of osteoblast and chondrocyte differentiation. *Histochem Cell Biol* 149: 313-323, 2018.
63. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JH, *et al*: Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. *Cell* 89: 773-779, 1997.
64. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR and de Crombrughe B: The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. *Cell* 108: 17-29, 2002.
65. Varma S, Orgel JP and Schieber JD: Nanomechanics of type I collagen. *Biophys J* 111: 50-56, 2016.
66. Murshed M: Mechanism of bone mineralization. *Cold Spring Harb Perspect Med* 8: a031229, 2018.
67. Kisling A, Lust RM and Katwa LC: What is the role of peptide fragments of collagen I and IV in health and disease? *Life Sci* 228: 30-34, 2019.
68. Chen Y, Ou Y, Dong J, Yang G, Zeng Z, Liu Y, Liu B, Li W, He X and Lan T: Osteopontin promotes collagen I synthesis in hepatic stellate cells by miRNA-129-5p inhibition. *Exp Cell Res* 362: 343-348, 2018.
69. An J, Yang H, Zhang Q, Liu C, Zhao J, Zhang L and Chen B: Natural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formation. *Life Sci* 147: 46-58, 2016.
70. Zhou H, Choong P, McCarthy R, Chou ST, Martin TJ and Ng KW: In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. *J Bone Miner Res* 9: 1489-1499, 1994.
71. van Leeuwen JP, van Driel M, van den Bemd GJ and Pols HA: Vitamin D control of osteoblast function and bone extracellular matrix mineralization. *Crit Rev Eukaryot Gene Expr* 11: 199-226, 2001.
72. Takahashi T, Kato S, Suzuki N, Kawabata N and Takagi M: Autoregulatory mechanism of Runx2 through the expression of transcription factors and bone matrix proteins in multipotential mesenchymal cell line, ROB-C26. *J Oral Sci* 47: 199-207, 2005.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.